ALS Lecture 2 - Intrathoracic Malignancy DONE Flashcards
2 main types of primary intrathoracic malignancy
lung carcinoma, pleura malignant mesothelioma
leading cause of cancer mortality in men and women
lung
90% of lung cancer cases are caused by
smoking
> 90% of lung cancer cases are in people
over 40
changes in lung cancer incidence and mortality have paralleled past trends in
cigarette smoking
marked increase in incidence and mortality of lung carcinoma in the 20th century followed the introduction of
manufactured cigarettes with addictive properties
risk of lung cancer progressively declines following
smoking cessation
cigarette smoke contains at least __ known carcinogens
43
other causes of lung carcinoma (5)
occupational carcinogens, environmental radon, air pollution, chronic lung disease, FH
radon once inhaled continues to
decay and emit alpha particles
occupations associated with radon higher risk (3)
air crew, nuclear fuel plant, power station workers
asbestos workers increased risk of cancer
5 fold
asbestos workers increased risk of smokers
11 fold
asbestos workers who are also smokers increased risk of cancer
53 fold
driver mutations
genetic factor of lung carcinoma, essential for tumour cell survival
common genetic mutations in adenocarcinoma in non-smokers
EGFR, ALK, RET, ROS1
common genetic mutations in adenocarcinoma in smokers
KRAS, BRAF
targeted drug for EGFR mutations
EGFR tyrosine kinase inhibitor
targeted drug for ALK mutations
ALK inhibitor
squamous cell carcinoma of the lung genetic mutation steps
- LOH of 3p and 9p 2. Oncogene OSX2 amplification in 3q
- TP53 inactivation
- LOH of 8p and 5q
which genes are ALWAYS inactivated in squamous cell carcinoma of the lung?
TP53, RB1
RB1 mutation is a hallmark of
small cell carcinoma
other genes involved in small cell carcinoma of the lung
PTEN, FGFR1, SOX2, SLIT, EPHA7
carcinoma of the lung symptoms (7)(9)
progressive SOB, cough, weight loss, chest pain, hoarseness, sputum, haemoptysis
symptoms related to lung carcinoma clinical features caused by tumour obstruction of airway (3)
pneumonia, abscess, lobar collapse
symptom related to lung carcinoma clinical features caused by tumour spread to pleura
pleural effusion
symptom related to lung carcinoma clinical features caused by tumour invasion of recurrent laryngeal nerve
hoarseness
symptom related to lung carcinoma clinical features caused by tumour invasion of oesophagus
dysphagia
symptom related to lung carcinoma clinical features caused by tumour invasion of phrenic nerve
diaphragm paralysis
symptom related to lung carcinoma clinical features caused by tumour invasion of chest wall
rib destruction
symptom related to lung carcinoma clinical features caused by tumour compressing SVC
superior vena cava syndrome
symptom related to lung carcinoma clinical features caused by apical tumour invasion of sympathetic ganglia
horner’s syndrome
symptoms related to lung carcinoma clinical features caused by pericardial involvement (2)
pericarditis, cardiac tamponade
common metastatic sites of lung carcinoma (6)
regional lymph nodes, bone, brain, liver, skin, adrenal glands
syndrome caused by ADH production by lung cancer cells
hyponatraemia
syndrome caused by ACTH production by lung cancer cells
Cushing syndrome
syndrome caused by parathyroid hormone production by lung cancer cells
hypercalcaemia
syndrome caused by calcitonin production by lung cancer cells
hypocalcaemia
syndrome caused by gonadotropins production by lung cancer cells
gynaecomastia
syndrome caused by serotonin and bradykinin production by lung cancer cells
carcinoid syndrome
syndrome caused by auto-antibodies against neuronal calcium channels production by lung cancer cells
Lambert-Eaton myaesthenic syndrome
other syndromes caused by lung cancer cells (4)
peripheral sensory neuropathy, acanthosis nigricans, Trousseau syndrome, finger clubing
diagnostic tools for lung carcinoma
CXR, CT, PET, MRI, bronchoscopy, cytology, biopsy, surgery
surgeries for lung cancer (2)
lobectomy, pneumonectomy
WHO classification of lung tumours
primary, benign and malignant, metastatic
main histological types of epithelial tumours (2)
non-small cell carcinoma, small cell carcinoma
types of non-small cell carcinoma (5)
adenocarcinoma, squamous cell, large cell, carcinoid, sarcoma
label the histological diagrams of carcinomas
done
atypical adenomatous hyperplasia histology
alveoli lined by atypical cuboidal epithelial cells
normal respiratory tract-type epithelium histology (3)
pseudostratified, columnar-shaped, ciliated
squamous metaplasia histology (1)
replacement of bronchial epithelium by mature squamous epithelium
dysplasia and carcinoma in situ histology (4)
disordered growth, loss of architecture and uniformity, pleomorphic, hyperchromatic nuclei
dysplasia and carcinoma in situ and cancer
precedes cancer, doesn’t always lead to it
squamous cell carcinoma cytology (3)
normal, metaplastic and highly atypical squamous epithelia, exfoliated cells in sputum
squamous cell carcinoma histology (4)
excessive growth of abnormal squamous cells, levels of differentiation (well, moderate, poor), intercellular bridges, keratinisation
small cell carcinoma histology (3)
small round blue cell tumour, high mitotic count, neurosecretory granules
choice of treatment for carcinoma of the lung depends on (2)
histological subtype, TNM stage
types of treatment for lung carcinoma (4)
surgery, chemo, radiotherapy, targeted and immunotherapy
TNM stages stand for
tumour, node, metastasis
T stage of TNM
1 - 4, 1 is small, 4 large
N stage of TNM
0-3, 0 no nodes involved, 3 lots
M stage of TNM
0 no mets, 1 mets
number stages cancer
1 - small, contained
2 - larger (in some cancers lymph nodes)
3 - larger, in nodes/nearby tissue
4 - mets
treatment for non-small cell lung cancer in stage 1-2 (2)
resection, radical radiotherapy (if unfit/refuse surgery)
prognosis for non-small cell lung cancer in stage 1-2
5 year survival 23-60%
treatment for non-small cell lung cancer in stage 3-4
palliative chemo/radiotherapy
prognosis for non-small cell lung cancer in stage 3-4
5 year survival <1%
treatment for small cell lung cancer, limited disease
radical chemo, radiotherapy
prognosis for small cell lung cancer, limited disease (3)
median survival 18months, <20% cured, 5 year survival 25%
treatment for small cell lung cancer, extensive disease
palliative chemo, radiotherapy
prognosis for small cell lung cancer, extensive disease
median survival 9 months
in non-small cell carcinomas with EGFR mutation we can use
tyrosine kinase inhibitors (e.g. erlotinib, gefitinib, osimertinib)
in non-small cell carcinomas with ALK translocation we can use
inhibit ALK (e.g. crizonitinib, ceritinib, alectinib, brigatinib, lorlatinib)
in non-small cell carcinomas with ROS1 translocation we can use (names)
crizonitib, ceritinib, entrectinib
if a cell carries PDL-1 it is
our own cell, so won’t attack it
some cancers develop PDL-1 to
trick our T-cells
some cancer drugs target the tumour’s fake ligand (PDL-1) or the T-cell receptor, e.g. (4)
pembrolizumab, nivolumab, atezolizumab, durvalumab,
malignant mesothelioma is a cancer of the
pleura
> 90% of cases of malignant mesothelioma are associated with previous
exposure to asbestos
latent period between exposure to asbestos and detection of malignant mesothelioma tumour
up to 50 years
with asbestos, the ____ ___ is more important than the ____ __ _____
cumulative dose, duration of exposure
Incidence of malignant mesothelioma in the UK is expected to peak in what year and why?
2020, asbestos banned 50 years ago
malignant mesothelioma usual age group
older adults
malignant mesothelioma gender
M > F, occupational exposure
malignant mesothelioma symptoms (11)
SOB, cough, chest pain, weakness, fatigue, weight loss, chest fullness, fever, sweating, pleurisy, pleural effusion
WHO classification of tumours of the pleura
primary (mesothelial, mesenchymal, lymphoproliferative), malignant, metastatic
main malignant mesothelioma histological types (4)
epitheloid, sarcomatoid, biphasic, desmoplastic
malignant mesothelioma locations can be (2)
localised, diffuse
possible surgery for malignant mesothelioma (2)
pneumonectomy, pleurectomy (not curative)
malignant mesothelioma prognosis
1 year survival, rarely >2 years
malignant mesothelioma compensation (2)
state, previous employer